
Halozyme Therapeutics, Inc.: updates and filings
Price
$91.35
November 20, 2026Market cap $10.8B
What Ploutos Investor adds for Halozyme Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 26% since Nov 5, 2026, when the 10-Q these figures come from was filed ($122.96 then, $91.35 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Sep 30, 2026Officer or director changeForm8-K
- Sep 22, 2026Material agreement entered, new material financial obligation, unregistered sale of sharesForm8-K
- Sep 18, 2026Other material eventsForm8-K
- Sep 16, 2026Other material eventsForm8-K
- Aug 18, 2026Officer or director changeForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 2, 2026Officer or director changeForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- May 7, 2026Shareholder voteForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 30, 2026Officer or director changeForm8-K
- Apr 24, 2026Amended articles or bylawsForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 23, 2026Additional annual meeting materialFormDEFA14A
- Mar 23, 2026Annual meeting proxy statementFormDEF 14A
- Mar 12, 2026Officer or director changeForm8-K
- Feb 17, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 17, 2026Results of operationsForm8-K
- Jan 28, 2026Results of operationsForm8-K
- Dec 9, 2025Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Sep 30, 2026 | 8-K | Officer or director change | Document |
| Sep 22, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares | Document |
| Sep 18, 2026 | 8-K | Other material events | Document |
| Sep 16, 2026 | 8-K | Other material events | Document |
| Aug 18, 2026 | 8-K | Officer or director change | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 2, 2026 | 8-K | Officer or director change | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| May 7, 2026 | 8-K | Shareholder vote | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 30, 2026 | 8-K | Officer or director change | Document |
| Apr 24, 2026 | 8-K | Amended articles or bylaws | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 12, 2026 | 8-K | Officer or director change | Document |
| Feb 17, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 17, 2026 | 8-K | Results of operations | Document |
| Jan 28, 2026 | 8-K | Results of operations | Document |
| Dec 9, 2025 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 21, 2001.
The full analysis
What do Halozyme Therapeutics's filings show?
The filings are where every one of Halozyme Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.